STAGE III RENAL CELL CANCER AJCC V8

This study tests whether adding a gut-health supplement called MO-03 to standard immunotherapy can help people with advanced clear cell kidney cancer live longer without their cancer growing. About 718 participants will receive either MO-03 or a placebo along with their usual tre…

This study tests whether adding a fiber supplement called inulin gel to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer better than immunotherapy alone. About 55 adults with kidney cancer that has spread or is locally advanced will …

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps control t…

This early-phase study tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The goal is to find …

This study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug bef…

This study tests whether adding precise, high-dose radiation to standard immunotherapy can better control advanced kidney cancer that has spread and cannot be surgically removed. About 240 participants will receive either immunotherapy alone or immunotherapy plus radiation to the…

This study looks at whether getting immunotherapy in the morning or afternoon makes it work better for people with advanced or spreading solid tumors. The body's internal clock (circadian rhythm) may affect how the immune system responds. Researchers will compare progression-free…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…